Subsequently, it was further approved for other immunological diseases, including Crohn’s disease and ulcerative colitis, especially for those who have failed to respond or are intolerant to either conventional therapy or anti-TNF therapy, or have medical contraindications to such therapies (Feagan et al., 2016; Sands et al., 2019). This evidence concerns the gene TNF and Crohn disease.